CEO to participate in ARVO SIG panel on oral medications for retinal diseases
ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42nd Annual Scientific Meeting
Ocuphire Pharma Participates In ARVO SIG Panel And ASRS 42nd Annual Scientific Meeting To Highlight APX3330 For Diabetic Retinopathy
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.